USSTOCK.TODAY
Market Closed
Log in Sign up

Moderna shares plunge over 25% despite announcement of cancer vaccine Phase 3 results

The Motley Fool +1 · ·by G4L

MRNA Moderna Inc
$199.33 +1.29%
View chart & analysis →
  1. 1Moderna's melanoma vaccine recorded a 42% reduction in the risk of recurrence or death when used in combination with Keytruda compared to Keytruda monotherapy in Phase 3.
  2. 2Moderna shares fell by more than 25% during the October 22 session.
  3. 3Among pancreatic cancer research patients, 55% remained without recurrence at the 17-month mark.

So what's the key point?

Results showed that Moderna's cancer vaccine reduced the risk of recurrence or death by 42%. However, despite this news, Moderna's stock price fell by more than 25%.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →